BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Seo KI, Yun BC, Li WJ, Lee SU, Han BH, Park ET. Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study. Clin Mol Hepatol 2017;23:74-9. [PMID: 28259115 DOI: 10.3350/cmh.2016.0052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Taherkhani R, Farshadpour F. Global elimination of hepatitis C virus infection: Progresses and the remaining challenges. World J Hepatol 2017; 9(33): 1239-1252 [PMID: 29312527 DOI: 10.4254/wjh.v9.i33.1239] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
2 Sølund C, Hallager S, Pedersen MS, Fahnøe U, Ernst A, Krarup HB, Røge BT, Christensen PB, Laursen AL, Gerstoft J, Bélard E, Madsen LG, Schønning K, Pedersen AG, Bukh J, Weis N; DANHEP group. Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation. Scand J Gastroenterol 2018;53:849-56. [PMID: 29720023 DOI: 10.1080/00365521.2018.1467963] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]